RxDoctor Payments Data

Thomas Willke, MD

Family Medicine · Hamilton, OHNPI 1184617888

Payments from drug & device makers

$10,116in general payments, 2019–2025

Across 715 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$701
  • GSK$629
  • Astellas Pharma US Inc$623
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$10,108100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,116 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$89,730
Medicare patients
247
Services billed
2,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$147,746
EliquisApixaban124$115,325
TrulicityDulaglutide52$111,246
OzempicSemaglutide70$88,248
MounjaroTirzepatide46$64,230
FarxigaDapagliflozin Propanediol32$47,709
RybelsusSemaglutide19$45,075
JanuviaSitagliptin Phosphate35$40,181
XareltoRivaroxaban27$37,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$25,312
Spiriva RespimatTiotropium Bromide18$17,617
Breo ElliptaFluticasone/Vilanterol33$16,744
SymbicortBudesonide/Formoterol Fumarate37$16,284
Chlorpromazine Hcl30$15,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$15,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$701$175,47798 claims
Boehringer IngelheimJardiance, Spiriva Respimat$464$165,363128 claims
Novo NordiskOzempic, Rybelsus$1,193$133,32389 claims
PfizerEliquis$309$115,325124 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$1,092$77,30380 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$629$58,17887 claims
MerckJanuvia$468$40,18135 claims
Johnson & JohnsonXarelto$434$37,51727 claims
Astellas Pharma US IncMyrbetriq$623$11,11115 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$69$9,43511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →